BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
Weibo Experienced a Surge in Advertising Revenue Worth USD 427 Mn in Q1 2022
On June 1, China’s leading social media platform Weibo released its annual financial statements for the first quarter of 2022. The company’s advertising revenue reached USD 427 million, up 10% year on year.
Jun 03, 2022 12:59 AM
Hong Kong IPO at a Glance: Weibo Corporation
The Twitter-like platform completed its secondary listing on December 8, 2021.
Dec 08, 2021 10:03 PM